New hope for ALS? early safety trial launches
NCT ID NCT06453668
First seen Jan 16, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This early-stage trial tests a drug called siplizumab in 48 adults recently diagnosed with ALS. The main goal is to check if the drug is safe and how the body processes it. Researchers will also look at how the drug affects immune cells and ALS symptoms over 52 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Skåne University Hospital Malmö
RECRUITINGMalmö, 205 02, Sweden
Contact
-
Studieenheten Akademiskt Specialistcentrum
RECRUITINGStockholm, 171 77, Sweden
Contact
-
Umeå University Hospital
RECRUITINGUmeå, 901 85, Sweden
Contact
Conditions
Explore the condition pages connected to this study.